Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CME Group Inc. SEC filings document the financial results, governance matters and market-infrastructure disclosures of a derivatives exchange and clearing operator. Form 8-K reports cover quarterly and annual results, GAAP and non-GAAP measures, pricing disclosures, material agreements and other events tied to the company’s trading, clearing, benchmark and market data activities.
The filings also describe clearing-house liquidity arrangements, including amendments to a multi-currency secured credit facility used for temporary liquidity needs related to clearing obligations and collateral mechanics. Proxy materials cover executive compensation, pay-versus-performance data, shareholder voting matters and governance. Other event reports have addressed officer transition disclosures and legal matters involving CME Group and the Board of Trade of the City of Chicago.
CME Group Inc. reported strong second-quarter 2026 results, with revenue of $1,706.2 million, operating income of $1,107.1 million, net income of $1,041.8 million and diluted EPS of $2.88. On an adjusted basis, operating income was $1,185.0 million, adjusted net income $1,081.7 million and adjusted diluted EPS $2.99.
Management highlighted that the first half of 2026 was the strongest in the company’s history, with record first-half revenue and adjusted profitability metrics. Q2 average daily volume was the third highest ever at 29.8 million contracts, and market data revenue rose 20% to a record $238.1 million. As of June 30, 2026, CME Group held $2.3 billion in cash and $3.4 billion of debt, while returning capital through approximately $468 million of dividends and $695 million of share repurchases in the quarter.
Tierney Robert J JR reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Robert J. Tierney Jr. received a grant of 645 shares of Class A common stock on June 25, 2026. The shares were valued at $225.00 per share for reporting purposes and were issued as part of the company’s annual equity compensation program for non-employee directors.
The award consists of fully vested shares under the CME Group Director Stock Plan and is not subject to any vesting conditions, meaning Tierney has full ownership upon grant. Following this equity grant, he directly holds 14,345 shares of CME Group Class A common stock.
GEPSMAN MARTIN J reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Martin J. Gepsman received a grant of 645 shares of Class A common stock on June 25, 2026. The shares were issued at an indicated value of $225.00 per share as part of the company’s annual equity compensation program for non-employee directors.
After this award, Gepsman directly holds 25,644 Class A shares. According to the disclosure, the granted shares are fully vested upon issuance and are not subject to any vesting conditions, highlighting that this is a compensation-related equity grant rather than an open-market purchase.
CME Group Inc. director William R. Shepard increased his stake in the company through a mix of market purchases and stock awards. On June 25, 2026, he made open-market purchases totaling 339.0999 shares of Class A common stock at $230.57 per share, including shares held indirectly through a trust.
On the same date he also acquired 1,067.0000 shares at a reference price of $225.00 per share through fully vested equity awards, shares taken in lieu of cash board retainers, and a dividend reinvestment plan under CME’s non‑employee director programs. Following these transactions, holdings reported include 260,442.3220 shares indirectly by trust and 3,620.7680 shares directly, indicating these moves are small relative to his overall position and largely compensation related.
Seifu Rahael reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Seifu Rahael received a grant of 645 shares of Class A common stock on June 25, 2026. The shares were issued at a value of $225.00 per share as part of the company’s annual equity compensation program for non-employee directors.
The footnote explains these are fully vested shares under the CME Group Director Stock Plan and are not subject to any vesting conditions. Following this award, Rahael directly holds 4,739 Class A shares, reflecting routine, compensation-related equity rather than an open-market purchase.
Suskind Dennis reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Dennis Suskind received a grant of 645 shares of Class A Common Stock on June 25, 2026 as equity compensation. The shares were valued at $225.00 per share for reporting purposes and were issued under the CME Group Director Stock Plan.
These shares are fully vested and not subject to any vesting conditions, meaning Suskind has immediate rights to them. Following this grant, he directly holds a total of 3,344 shares of CME Group Class A Common Stock. This is a routine, compensation-related award rather than an open-market purchase or sale.
SIEGEL HOWARD J reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Howard J. Siegel reported stock awards of Class A Common Stock as part of his non-employee director compensation. On June 25, 2026, he received 422 shares at $225 per share as a fully vested annual equity grant under the CME Group Director Stock Plan.
On the same date, he also received 645 fully vested shares at $225 per share, issued at his election in lieu of all or part of his annual cash retainer, with the share count based on the closing price on the grant date. Separately, the filing shows 21,873 shares of Class A Common Stock held indirectly by a trust.
Mulchrone Patrick J reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Patrick J. Mulchrone received a grant of 645 shares of Class A common stock as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. The grant price was $225.00 per share, and the shares are fully vested with no vesting conditions. After this award, he directly holds 29,130 Class A shares and has an additional 25,000 shares reported as indirectly owned by his spouse.
Maloney Patrick W reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Patrick W. Maloney received a grant of 645 fully vested shares of Class A common stock at $225 per share. The award was issued as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. Following this grant, Maloney directly holds 4,743 shares of Class A common stock.
Lucas Deborah J reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Deborah J. Lucas received an equity award of Class A common stock. She was granted 645 fully vested shares at a price of $225 per share as part of CME Group’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. Following this grant, she directly holds 4,533 Class A shares. This is a compensation-related stock award, not an open-market purchase.